The Launch of my-Cardia ECG Products and Services in Thailand
Mango Wellness Co., Ltd. and My-Cardia Thailand Co., Ltd. to begin exclusive distribution of CB Scientific’s FDA & CE-cleared EKG products to an expansive private and government hospital network
ESCONDIDO, Calif. (Oct. 8, 2020) (Globe Newswire) – via Network Wire – CB Scientific. Inc. (OTC:CBSC) (“CBSC” or the “Company”), a provider of innovative products and services for the ambulatory noninvasive cardiac monitoring space, announces today the targeted start of cardiac lab services operations in the country of Thailand through the Company’s exclusive authorized distributor, Mango Wellness Co., Ltd. (MWC) and My-Cardia Thailand Co., Ltd. (MCT). beginning Oct. 29, 2020.
Under terms of the distribution agreement, Mango Wellness Co., Ltd. and My-Cardia Thailand Co. Ltd. will be the exclusive distributor for CBSC’s proprietary FDA and CE-cleared EKG myCam Cardiac Event Monitor, the interactive cloud-based my-Cardia acquisition software, and the associated smartphone apps for both iOS and Android platforms in Thailand. The my-Cardia product line is designed specifically for the Remote Cardiac Ambulatory ECG market to help in the detection of abnormal heart rhythms while providing improved compliance for the patient, as well as more timely, convenient and accurate information for the physician.
“Mango Wellness and My-Cardia Thailand is committed to providing and delivering the best wellness and healthcare ECG services to more than 1,300 private and government hospitals in Thailand to assist our healthcare providers and physicians in early detection and diagnosis of a patient’s abnormal cardiac rhythm,” said Joe Chan, executive director for Mango Wellness and My-Cardia Thailand. “With a total population of 69 million people in Thailand, where cardiovascular disease has increased steadily over the past decade and is now the major leading cause of death in our country, this clearly indicates the critical need for innovative diagnostic products and services like these in Thailand. Offering the my-Cardia line of Ambulatory ECG devices and software will provide an alternative monitoring choice for our customers to improve the earlier detection of problematic cardiac rhythms which will help to improve patients’ lives.”
Charles Martin, CBSC CEO added, “Mango Wellness and My-Cardia Thailand is a great partner for the distribution of our products and services in Thailand. They have the reputation and clinical experience there to help make our my-Cardia products a market leader in their country. This launch, together with the upcoming targeted distribution start-ups in Malaysia and Singapore in the coming months and our continued work towards NMPA (National Medical Products Administration, formerly CFDA) certification in China, will go a long way towards helping our company establish a solid footprint in the Ambulatory noninvasive ECG monitoring market in Asia.”
The distribution agreement may be expanded with additional products and territories in the future. Financial terms of the agreement were not disclosed.
CB Scientific plans to make further announcements to keep its shareholders, industry participants and the public markets informed through press releases and regulatory filings as new developments occur.
CB Scientific, Inc. Company Contact Information:
340 State Place
Escondido, CA 92029
Mango Wellness Co., Ltd./My-Cardia Thailand Co., Ltd. Company Contact Information:
Mango Wellness Co., Ltd.
Glas Haus Building, Level P, Unit PO1
1 Sukhumvit 25, North Klongtoey
Wattana, Bangkok, Thailand 10110
My-Cardia Thailand Co., Ltd.
190 Sutthisan Road, Intersection 1
Bangkok, Thailand 10400
+66 (0) 21015576 – Mango Wellness
+66 (0) 971566481 – My-Cardia Thailand
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.